<DOC>
	<DOCNO>NCT00282945</DOCNO>
	<brief_summary>The purpose study determine whether marker b-cell function predict change B-cell function time patient type 2 diabetes mellitus ( T2DM ) randomize treatment metformin rosiglitazone .</brief_summary>
	<brief_title>Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone</brief_title>
	<detailed_description>The study terminate 17-Jul-07 due concern long-term cardiovascular safety Avandia slow patient enrollment . There specific safety issue raise within trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female type diabetes mellitus ( diagnosed via ADA criterion ) , newly diagnose treatmentnaive ( diet exercise ) HbA1c range 7 9 % . 4570 year age . Evidence history clinically significant hematological , renal , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( exclude untreated , asymptomatic , seasonal allergy ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>